MDX-1097

DB18383ExperimentalProtein Based Therapies

MDX-1097 is a chimeric monoclonal antibody directed against the kappa myeloma antigen (KMA).

Mechanism: Pharmacologically active on Immunoglobulin kappa light chain
Curator reviewed
Code names: MDX-1097

Resolves to

Compound

Targets

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with MDX-1097, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.